Could AstraZeneca shares tumble if its vaccine is halted for under-30s?

The AstraZeneca share price has come under pressure in recent days as the UK’s medical authorities consider new restrictions on its vaccine, and EU nations continue to halt the AZ vaccine rollout amid the safety uncertainty.

  • Year-to-date decline of 2.35% for AstraZeneca shares
  • UK could restrict AstraZeneca vaccine for under-30s
  • The European Medicines Agency (EMA) to reveal findings on links to blood clots
  • Moderna vaccine in line to take advantage
  • Want to trade AstraZeneca shares? Open an account today

The AstraZeneca (AZN.L) share price has plunged by 3.9% in the last week following increasing uncertainty surrounding its Covid-19 vaccine’s links to rare blood clots, known as thromboembolic events.

On 21 March 2021, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) published fresh data on the safety of the AstraZeneca vaccine, stating that 30 cases of blood clots had been discovered in 18.1 million doses.

Is the MHRA set to take a view on the vaccine’s safety record?

The UK’s vaccine programme has been one of the quickest and most comprehensive in the world. The Oxford-AstraZeneca vaccine has been one of two Covid-19 vaccines used in the nationwide rollout, along with the Pfizer (PFE.N) and BioNTech (BNTX.O) vaccines respectively.

However, a Channel 4 News report released on 5 April 2021 suggested that the MHRA has been ‘urged’ to ‘pause or restrict’ usage of the AstraZeneca vaccine amid safety fears among younger people. The MHRA is actively ‘scrutinising’ data which suggests young women under 30 are at heightened risk of a ‘potentially fatal blood clot’ from the vaccine than Covid-19 itself.

Although the MHRA’s chief executive, Dr June Raine, insisted that people should ‘continue to get their vaccine when invited to do so’, the prospect of fresh regulatory action has created a short-term bear market for AstraZeneca shares.

Why is the Netherlands the latest EU nation to curb AstraZeneca vaccine rollout?

The AstraZeneca share price fall has also factored in recent rows over vaccine deliveries across the European Union (EU) bloc. The British-Swedish firm has also been hit by a string of EU nations opting to temporarily halt the rollout of the vaccine. The Netherlands is the most recent to scrap 10,000 planned vaccinations after reporting five new cases of blood clotting in females aged between 25 and 65.

The EMA has steadfastly insisted that the AstraZeneca vaccine is ‘safe and effective' to use, in recent weeks. However, the EMA’s safety committee is due to reveal its ‘evaluation of a safety signal’ with AstraZeneca based on ‘cases of thromboembolic events’.

Why are Moderna shares surging in light of the AstraZeneca vaccine uncertainty?

If the MHRA recommends limiting the use of the Oxford-AstraZeneca vaccine to individuals over 30, the Moderna vaccine looks set to benefit as the primary vaccine for Britain’s young adult population.

The UK government’s Vaccines Minister Nadhim Zahawi insists that the government will be ‘led by what the regulator and scientists say is the right thing to do’.

The US-developed Moderna (MRNA.O) vaccine has become the third Covid-19 vaccine to be rolled out in the UK, with 17 million doses ordered by the UK government. The first Moderna batch has reached Wales and Scotland and it will be deployed in England from the third week of April.

With the Moderna vaccine tipped to replace the AstraZeneca vaccine in the UK’s rollout to younger people, it’s no surprise that Moderna shares have soared over 16% in the last week from 118p to highs of 137.67p, showing signs of returning to those February highs.

Ready to buy or sell the AstraZeneca share price?

Take your position on UK shares for just a small initial deposit with CFDs.

Open an account to start trading on UK shares

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.